Business Wire

Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows

Share

With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425843193/en/

VIO 3n Fire

Five configurations for precise surgical and endoscopic applications

With over 100 years of experience in electrosurgery, Erbe continues to innovate with the introduction of five new VIO® 3n configurations: Fire, Water, Metal, Timber, and Stone. Each configuration is designed to meet the unique demands of different surgical and endoscopic procedures, providing preprogrammed CUT, COAG, and dissection settings that enhance efficiency and reduce complexity. The VIO® 3n features trusted Erbe electrosurgical modes such as endoCUT®, preciseSECT, and pulsedAPC, ensuring reproducible tissue effects across specialties, also introducing our new mode endoCUT® U, developed for “underwater” applications.

Beyond precise tissue effect adjustment, the VIO® 3n prioritizes intuitive usability: its interface with stepGUIDE supports surgical teams with logical menu navigation and real-time notifications, simplifying setup and operation. Additionally, the generator seamlessly integrates with other Erbe units, such as APC 3 and IES 3, as well as Erbe instruments and accessories allowing flexible adaptation to existing workstations.

VIO® seal: The first VIO® generator for bipolar applications

As a specialized solution for bipolar electrosurgical procedures, the VIO® seal is a significant addition to the Erbe portfolio. Designed for use with TriSect rapide®, BiClamp® and standard bipolar instruments, the unit can function as a standalone solution or in combination with the VIO® 3n as well as existing installed bases like the VIO® D and S series. Featuring digital instrument recognition, it aligns perfectly with surgical workflows.

A key feature: when paired with another VIO® generator, the VIO® seal enables simultaneous bipolar activation, expanding the possibilities of surgical procedures.

A future-proof electrosurgical solution built to fit various clinical demands

With the launch of the VIO® 3n and VIO® seal, Erbe takes another step toward becoming a comprehensive solution provider. The combination of tailored configurations, high-performance workflows, and trusted Erbe technology creates a platform designed to meet the specific needs of various medical specialties.

“After more than 100 years of electrosurgery and over 100,000 VIO® electrosurgical generators sold, Erbe is launching the next generation – the VIO® 3n,” explains Dr. Helmut Scherer, Chief Technology Officer of the Erbe Group. “With the VIO® 3n, the successful operating concept of the VIO® 3 is transferred to the next technology generation and made available for various medical disciplines.”

The new systems will be available in the CE market and CE related countries from April 2025.

About Erbe Elektromedizin

Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OR teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.

Fields of activity

  • Imaging
  • Endoscopy
  • Electrosurgery
  • Plasma surgery
  • Thermofusion
  • Hydrosurgery
  • Cryo technology

An international network

  • 20 international sales and service units
  • 5 production sites
  • Erbe is active in 110 international markets.

The Erbe workforce

  • 2,100 employees worldwide
  • Some 1,100 of them in Germany

View source version on businesswire.com: https://www.businesswire.com/news/home/20250425843193/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye